Jefferies Group’s Amneal Pharmaceuticals AMRX Stock Holding History

Jefferies Group’s Portfolio AMRX Stock Details AMRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-67,885	Closed	-$487K	–	2680
2019 Q2	$487K	Buy	+67,885	New	+$694K	﹤0.01%	1682
2019 Q1	–	Sell	-10,648	Closed	-$144K	–	2293
2018 Q4	$144K	Buy	+10,648	New	+$192K	﹤0.01%	1908

Other funds holding AMRX

Fosun International Hong Kong, China $446M AUM 13.33% 1-Year Est. Return

TGHSA

TPG Group Holdings (SBS) Advisors Fort Worth, Texas $10.1B AUM 22.58% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Jefferies Group's AMRX Position: Q3 2019 in Review

Jefferies Group sold out of Amneal Pharmaceuticals (AMRX) in Q3 2019, closing a stake of 67,885 shares — an estimated $487K sold.

Jefferies Group first reported a position in AMRX in Q4 2018 and held it in 2 quarters. The position peaked at $487K in Q2 2019. 121 funds tracked by Wall St. Rank hold AMRX as of Q3 2019.

Jefferies Group reported no remaining Amneal Pharmaceuticals position as of Q3 2019 after selling out during the quarter.
Jefferies Group sold 67,885 Amneal Pharmaceuticals shares in Q3 2019, an estimated $487K.
Jefferies Group first reported a position in Amneal Pharmaceuticals in Q4 2018 and held it in 2 quarters.
Jefferies Group's Amneal Pharmaceuticals position peaked at $487K in Q2 2019.
121 funds tracked by Wall St. Rank held Amneal Pharmaceuticals as of Q3 2019.

Based on Jefferies Group's 13F filing for Q3 2019, filed 13 Nov 2019.